<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">12884295</PMID>
      <DateCompleted>
        <Year>2003</Year>
        <Month>09</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2014</Year>
        <Month>11</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0014-2980</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>33</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2003</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of immunology</Title>
          <ISOAbbreviation>Eur J Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sensitivity of IL-5 production to the cAMP-dependent pathway in human T cells is reduced by exogenous IL-2 in a phosphoinositide 3-kinase-dependent way.</ArticleTitle>
        <Pagination>
          <StartPage>2206</StartPage>
          <EndPage>2215</EndPage>
          <MedlinePgn>2206-15</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The cAMP-dependent pathway plays an important role in the regulation of T cell-mediated immune responses by inhibition of T cell proliferation, activation and production of Th1-like cytokines. Depending on costimulatory signals and on the activation status of T cells, cAMP also regulates the production of Th2-like cytokines, yet the mechanism is not completely defined. We investigated the effect of costimulation with IL-2 on cAMP-mediated inhibition of IL-5 secretion and the signaling pathways involved in these effects in freshly isolated, alpha-CD3/alpha-CD28-stimulated human T lymphocytes. We demonstrate that IL-2 counteracts the cAMP-mediated inhibitory effects on IL-5 secretion by the modulation of phosphoinositide 3-kinase (PI3-K)-dependent signaling. Our results indicate that phosphorylation of cAMP-responsive element-binding protein (CREB) and the activity of the small GTPase Rap1 are unlikely involved in the protective effect of IL-2. Instead, the effect of IL-2 may be mediated by the PI3-K-dependent inactivation of the forkhead-related transcription factor FKHR-L1, down-regulation of p27(kip) and abrogation of the cAMP-mediated inhibition of activator protein (AP)-1 binding activity. Together, our results indicate that increased IL-2-dependent PI3-K signaling leads to impaired negative feedback control of the production of Th2-type cytokine IL-5 by the cAMP-dependent pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Heijink</LastName>
            <ForeName>Irene H</ForeName>
            <Initials>IH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Allergology, University Hospital Groningen, Groningen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kauffman</LastName>
            <ForeName>Henk F</ForeName>
            <Initials>HF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Postma</LastName>
            <ForeName>Dirkje S</ForeName>
            <Initials>DS</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Monchy</LastName>
            <ForeName>Jan G R</ForeName>
            <Initials>JG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vellenga</LastName>
            <ForeName>Edo</ForeName>
            <Initials>E</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Eur J Immunol</MedlineTA>
        <NlmUniqueID>1273201</NlmUniqueID>
        <ISSNLinking>0014-2980</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015848">Interleukin-5</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018808">Transcription Factor AP-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>147604-94-2</RegistryNumber>
          <NameOfSubstance UI="D050760">Cyclin-Dependent Kinase Inhibitor p27</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>E0399OZS9N</RegistryNumber>
          <NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.-</RegistryNumber>
          <NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D020827">rap1 GTP-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K7Q1JQR04M</RegistryNumber>
          <NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050760" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p27</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015848" MajorTopicYN="N">Interleukin-5</DescriptorName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018808" MajorTopicYN="N">Transcription Factor AP-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020827" MajorTopicYN="N">rap1 GTP-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2003</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2003</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2003</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>5</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">12884295</ArticleId>
        <ArticleId IdType="doi">10.1002/eji.200323804</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
